6. Yucai Wang, Shouhao Zhou, Fang Yang, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-1019.
18 款 PD-1/PD-L1/CTLA-4 免疫抑制剂使用宝典 肿瘤的治疗方式除了手术、放疗、化疗以及靶向治疗等,免疫治疗也给肿瘤患者的治疗带来了新的希望。近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)为代表的免疫疗法通过激活患者自身 T 淋巴细胞的抗肿瘤免疫功能,发挥杀灭肿瘤细胞的作用,在临床上已被广泛使...
PD-1 And PD-L1 Inhibitors Market Analysis The PD-1 And PD-L1 Inhibitors Market size is estimated at USD 63.73 billion in 2025, and is expected to reach USD 145.56 billion by 2030, at a CAGR of 17.96% during the forecast period (2025-2030). ...
However, the main treatment modalities for patients with early and intermediate stage colorectal cancer (CRC) are surgery, and the role of PD-1/PD-L1 inhibitors in these patients is not yet clear. Therefore, this study aims to review the treatment progress of PD-1/PD-L1 inhibitors for ...
PD1- PDL-1 inhibitors act against pathways involved in adaptive immune suppression resulting in immune checkpoint blockade. Within the last four years two PD-1 and three PD-L1 inhibitors have been utilized in clinical practice against a variety of malignancies. Focus was initially placed on targetin...
The purpose of this review is to synthesize current data on the expression of PD-L1 in breast cancer and on the preliminary clinical results of PD-1/PD-L1 inhibitors in breast cancer patients. In breast cancer, PD-L1 expression is heterogeneous and is generally associated with the presence ...
Programmed cell death protein-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) inhibitors are drugs used for treating various cancers.
PD-1/PD-L1检查点抑制剂不再是简单“增强”免疫反应,而是让肿瘤发病过程中出现缺陷的免疫系统“恢复正常”。“恢复正常”的免疫系统可以使部分患者实现长期生存获益,由于单药PD-1/PD-L1检查点抑制剂的客观缓解率仅为20%左右,使得获益人群有限。 (A Paradigm Shift in Cancer Immunotherapy: From Enhancement to No...
mechanisms of PD-L1 expression and its effect on T-cells (“The PD-1:PD-L1 T-cells inhibitory checkpoint”); 4 - clinico-pathological correlation and prognostic value of PD-L1 expression in tumors (PD-L1 expression and significance in tumors); and, 5 and 6 -, the role of PD-L1 in ...
Therefore, PD-1/PD-L1 inhibitors can restore T cells from the failing state by blocking the binding of PD-1/PD-L1, which effectively kills tumor cells [5], [6]. Tumor cells utilize the immunosuppressive function of PD-L1 to escape recognition by T cells, and prolonged exposure to PD-...